Insider Selling: Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Major Shareholder Sells $114,655.70 in Stock

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 10,490 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $10.93, for a total transaction of $114,655.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Thursday, July 11th, Matt Davidson sold 13,212 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $11.58, for a total transaction of $152,994.96.
  • On Monday, July 8th, Matt Davidson sold 12,529 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $11.27, for a total transaction of $141,201.83.
  • On Tuesday, July 2nd, Matt Davidson sold 33,521 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $11.63, for a total transaction of $389,849.23.
  • On Tuesday, June 25th, Matt Davidson sold 210 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $10.04, for a total transaction of $2,108.40.
  • On Thursday, June 13th, Matt Davidson sold 2,131 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $9.65, for a total transaction of $20,564.15.
  • On Tuesday, June 11th, Matt Davidson sold 4,345 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $8.49, for a total transaction of $36,889.05.
  • On Thursday, June 6th, Matt Davidson sold 5,507 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $7.27, for a total transaction of $40,035.89.
  • On Monday, June 3rd, Matt Davidson sold 4,110 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $7.36, for a total transaction of $30,249.60.
  • On Wednesday, May 29th, Matt Davidson sold 2,100 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.41, for a total transaction of $17,661.00.
  • On Thursday, May 23rd, Matt Davidson sold 2,422 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.80, for a total transaction of $21,313.60.

VRCA opened at $10.34 on Friday. Verrica Pharmaceuticals Inc has a twelve month low of $6.44 and a twelve month high of $19.10. The business’s fifty day moving average price is $9.77. The firm has a market capitalization of $279.96 million and a PE ratio of -7.33.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02). On average, equities research analysts expect that Verrica Pharmaceuticals Inc will post -1.25 EPS for the current fiscal year.

VRCA has been the subject of several recent analyst reports. HC Wainwright increased their price objective on shares of Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Zacks Investment Research cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th.

Several institutional investors and hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund acquired a new stake in Verrica Pharmaceuticals in the fourth quarter worth $28,000. Bank of New York Mellon Corp grew its holdings in Verrica Pharmaceuticals by 39.1% in the fourth quarter. Bank of New York Mellon Corp now owns 16,662 shares of the company’s stock worth $136,000 after purchasing an additional 4,681 shares during the period. Northern Trust Corp grew its holdings in Verrica Pharmaceuticals by 7.5% in the fourth quarter. Northern Trust Corp now owns 67,028 shares of the company’s stock worth $546,000 after purchasing an additional 4,689 shares during the period. Asymmetry Capital Management L.P. grew its holdings in Verrica Pharmaceuticals by 12.0% in the first quarter. Asymmetry Capital Management L.P. now owns 70,458 shares of the company’s stock worth $762,000 after purchasing an additional 7,576 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Verrica Pharmaceuticals by 31.7% in the fourth quarter. Geode Capital Management LLC now owns 36,906 shares of the company’s stock worth $300,000 after purchasing an additional 8,885 shares during the period. Institutional investors own 34.31% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

See Also: Risk Tolerance

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.